SAN DIEGO, Nov. 18, 2019 -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional.

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational New Drug (IND) amendment with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1b/2a clinical trial of its lead program, HST 001 for the treatment of androgenic alopecia in men. The submission is intended to expand Histogen’s IND to be a Phase 1b/2a clinical trial to assess the safety, tolerability and efficacy of HSC, as well as determine optimal dosing in male pattern hair loss. “We are excited to see our pipeline continue to progress with this IND submission for HST 001 as we take the next step towards making a treatment available for androgenic alopecia,” said Richard W. Pascoe, Histogen’s Chairman and Chief Executive Officer.

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on its human extracellular matrix (hECM) for cartilage regeneration in the Journal of Orthopaedic and Trauma Care. Histogen has developed a patented embryonic-like hECM that contains components associated with stem cell niches in the body and scar-less healing of fetal skin including laminins, osteonectin, decorin, hyaluronic acid, collagen type IV, SPARC, CXCL12, NID1, NID2, NOTCH2, tenascin, thrombospondin, fibronectin, versican, and fibrillin-2. In vitro studies have demonstrated that HST 003 induces the proliferation of human mesenchymal stem cells (hMSCs) while retaining their stemness and causing them to down regulate collagen 1 and up regulate aggrecan, both important characteristics of forming hyaline cartilage.

SAN DIEGO, Nov. 05, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent.

Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of HST 002 for the treatment of facial folds and wrinkles. “The submission of this Investigational Device Exemption for HST 002 is an important milestone for Histogen as we continue to advance our development pipeline following the recent submission of our Investigational New Drug Application Amendment for HST 001 for hair loss,” said Richard W. Pascoe, Histogen’s Chairman and Chief Executive Officer. In addition to clinical development of HST 002, Histogen recently announced the filing of an IND amendment for its lead product for hair loss (HST 001) and the anticipated IND filing for its joint cartilage regeneration (HST 003) product candidate in 2020.

Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Histogen Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, announced today that it will be featured as a presenting company at the BIO CEO & Investor Conference taking place February 10-11, 2020 at the New York Marriott Marquis.

In 2005 Steven Mento was appointed CEO of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). First, this article will compare...

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences. Histogen has developed a cell conditioned media (CCM) that is embryonic-like in composition and that has been shown to stimulate stem cells in vivo. In a spinal disc study, HST 004 reversed inflammation and protease activity and stimulated aggrecan secretion in the thrombin-induced rabbit ex vivo model.

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men. Under this IND, Histogen intends to initiate a Phase 1b/2a clinical trial of HST 001, a Hair Stimulating Complex (HSC), in the second quarter of 2020. This clinical trial is designed to assess the safety, tolerability and efficacy of HST 001, as well as determine optimal dosing in male pattern hair loss.

Conatus Pharmaceuticals Inc. (CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockholder approvals required pursuant to the terms of its merger agreement with Histogen Inc. Conatus announced it needs additional time to solicit stockholder votes in order to obtain a quorum for the meeting and affirmative votes from a majority of the outstanding shares of Conatus’ common stock, which is required for the approval of the reverse stock split (Proposal 2). The reverse stock split must be approved by a majority of the outstanding shares in order for the merger to close.

Conatus Pharmaceuticals Inc. (CNAT) and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction. The combined company will operate under the name Histogen, Inc., is expected to trade on the Nasdaq Capital Market under a new ticker symbol still to be determined and will focus on advancement of its patented technology for dermatological and orthopedic indications. “After completing a comprehensive review of multiple strategic alternatives, we determined that the proposed merger with Histogen would provide the best opportunity for Conatus shareholders moving forward,” said Steven J. Mento, Ph.D., President, Chief Executive Officer and co-founder of Conatus.

Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Conatus Pharmaceuticals Inc. (CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional investors with voting assessment and recommendations, have recommended that Conatus stockholders vote “FOR” Conatus’ proposed merger with Histogen Inc. (“Histogen”) and “FOR” Conatus’ proposed reverse stock split, both of which are to be considered at Conatus’ upcoming special meeting of stockholders to be held on May 21, 2020. “We are very pleased that these highly influential proxy advisor firms have recommended that our stockholders vote in favor of the proposals to merger with Histogen and the required reverse stock split,” said Steven J. Mento, Ph.D., President, Chief Executive Officer and co-founder of Conatus.

Conatus Pharmaceuticals Inc. (CNAT) today announced financial results for the first quarter ended March 31, 2020 and provided an update on its strategic process. In January 2020, Conatus announced that it had entered into a definitive agreement with Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction. The combined company will operate under the name Histogen Inc., is expected to trade on the Nasdaq Capital Market under the ticker symbol HSTO and will focus on advancement of its patented technology for dermatological and orthopedic indications.

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Conatus Pharmaceuticals Inc. (CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its strategic process. In January 2020, Conatus announced that it had entered into a definitive agreement with Histogen Inc., a privately-held regenerative medicine company focused on developing patented, innovative technologies that replace and regenerate tissues in the body for aesthetic and therapeutic markets, pursuant to which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction. The combined company will operate under the name Histogen Inc., is expected to trade on the Nasdaq Capital Market under the ticker symbol HSTO and will focus on advancement of its regenerative tissue technology for dermatological and orthopedic indications.